Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients with Acute Myeloid Leukemia Undergoing TBI

Inclusion Criteria

• Cohort TMLI+FLT: AML patients >= 18 years old and planning to undergo TMLI radiation as part of the conditioning for allogeneic hematopoietic cell transplantation either on COH 14012, IRB 17505, or IRB 19518, or off-study TMLI (with active disease) that agree to participate in optional FLT PET imaging
• Cohort TMLI: AML or ALL patients >= 18 years old and planning to undergo TMLI radiation as part of the conditioning for allogeneic hematopoietic cell transplantation either on COH 14012, IRB 17505 or IRB 19518, or off-study TMLI (with active disease)
• Cohort TBI: First or second remission AML or ALL patients that are planned to receive undergo allogeneic transplant with myeloablative dose TBI regimen (range 12 Gy – 13.5 Gy) as part of their standard of care
• Cohort TBI: Documented written informed consent of participant
• Cohort TBI: Age >= 18 to =< 60 years
• Cohort TBI: Patients who have not received a prior transplant
• Cohort TBI with FLT: First or second remission AML or ALL patients that are planned to undergo allogeneic transplant with myeloablative dose TBI regimen (range 12 Gy -13.5 Gy) as part of their standard of care
• Cohort TBI with FLT: Documented written informed consent of participant
• Cohort TBI with FLT: Age >= 18 to =< 60 years
• Cohort TBI with FLT: Patients who have not received a prior transplant
• Cohort TBI with FLT: Agree to participate in optional FLT PET imaging
• COHORT AML DISEASE: AML patients >= 18 years old with active AML disease